Pachet de 10 flacoane5 în stocEconomisiți 22%Retatrutide 15 mg
Peptid de cercetare tri-agonist GLP-1 / GIP / glucagon
Retatrutide tri-agonist research peptide, Australian-shipped. Lab-verified ≥99% purity.
Numai pentru uz de cercetare. Acest compus se vinde strict pentru cercetare in vitro și scopuri de laborator și nu este destinat consumului uman sau uzului terapeutic. Prin cumpărare confirmi că ești un cercetător calificat și ești de acord cu declinarea noastră completă.
Mai sunt doar 5 pachete
Peptid de cercetare agonist al trei receptori, studiat pentru efectele combinate asupra căilor de semnalizare GLP-1, GIP și glucagon în aplicații de cercetare metabolică.
Retatrutide is a synthetic tri-agonist research peptide that activates the GLP-1, GIP, and glucagon receptors simultaneously. It is part of a new generation of incretin-receptor research compounds developed to study combined activation of multiple metabolic pathways. Quantum Labs supplies Retatrutide as a lyophilised powder for Australian research applications.
Retatrutide is studied alongside other incretin-receptor agonists — semaglutide (single-agonist GLP-1) and tirzepatide (dual-agonist GLP-1/GIP) — in pre-clinical and clinical research literature. The tri-agonist mechanism is the distinguishing feature that places it in its own research category. Material is HPLC-verified to ≥99% purity and ships from Australian stock; supplied for laboratory research use only.
Mecanism
Studiat pentru agonismul simultan al receptorilor GLP-1, GIP și glucagon. Cercetare asociată cu markerii ratei metabolice, sațietății și cheltuielii energetice în populațiile de studiu.
Verificat HPLC față de o specificație de puritate ≥99%. Testat independent de laboratoare terțe acreditate.
Retatrutide — întrebări frecvente
What is Retatrutide?
Retatrutide is a synthetic tri-agonist research peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors. It is a newer-generation incretin-receptor research compound.
Is Retatrutide legal in Australia?
Retatrutide is not an approved therapeutic in Australia and remains available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies Retatrutide for research use only — it is not a substitute for prescription weight-loss medication.
What is the difference between Retatrutide and Tirzepatide?
Tirzepatide is a dual-agonist activating GLP-1 and GIP receptors. Retatrutide is a tri-agonist activating GLP-1, GIP, and glucagon receptors. The added glucagon-receptor activity is the distinguishing pharmacological feature of Retatrutide.
What is the difference between Retatrutide and Mounjaro?
Mounjaro is the brand name for the approved prescription medicine tirzepatide. Retatrutide is a separate research peptide with an additional glucagon-receptor agonism. They are different molecules studied in parallel research literature. Quantum Labs does not supply prescription medicines.
What is the typical Retatrutide research dosage?
Published clinical research has used Retatrutide doses across a wide titration range. Research-protocol dosing varies by model. Human therapeutic dosing is not established. Quantum Labs supplies this compound for laboratory and pre-clinical research use only. It is not represented for human therapeutic use, and questions about clinical dosing, treatment effects, or personal use should be directed to a qualified medical practitioner.
Ghiduri legate de Retatrutide
Cercetătorii explorează și
Pachet de 10 flacoaneEconomisiți 22%MOTS-c
Pulbere liofilizată10 mg · 2 strengths
Peptid metabolic de origine mitocondrială
În 2 stack-uri
Pachet de 10 flacoaneEconomisiți 17%5-Amino-1MQ
Pulbere liofilizată50 mg · 3 strengths
Compus de cercetare inhibitor NNMT
Pachet de 10 flacoaneEconomisiți 15%L-Carnitine
Sterile solution10 ml × 600 mg/ml
Transportor mitocondrial de acizi grași
În 1 stack